NDA 022561 · Emd Serono INC
Mavenclad
Cladribine · Oral · Purine Antimetabolite
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Mar 29, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
147
32 Phase 3, 31 recruiting
FAERS reports
9,967
7,443 serious, 717 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: MALIGNANCIES AND RISK OF TERATOGENICITY Malignancies Treatment with MAVENCLAD may increase the risk of malignancy. MAVENCLAD is contraindicated in patients with current malignancy. In patients with prior malignancy or with increased risk of malignancy, evaluate the benefits and risks of the use of MAVENCLAD on an individual patient basis. Follow standard cancer screening guidelines in patients treated with MAVENCLAD [see Contraindications (4) and Warnings and Precautions (5.1) ] . Risk of Teratogenicity MAVENCLAD is contraindicated for use in pregnant women and in females and males of reproductive potential who do not plan to use effective contraception because of the potential for fetal harm. Malformations and embryolethality occurred in animals. Exclude pregnancy before the start of treatment with MAVENCLAD in females of reproductive potential. Advise females and males of...
What it is approved for
From the label in effect May 27, 2026.
MAVENCLAD is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS [see Warnings and Precautions (5) ]. Limitations of Use MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile [see Warnings and Precautions (5) ]. MAVENCLAD is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS . ( 1 , 5 ) Limitations of Use MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile . ( 1 , 5 )
Mechanism: The mechanism by which cladribine exerts its therapeutic effects in patients with multiple sclerosis has not been fully elucidated but is thought to involve cytotoxic effects on B and T lymphocytes through impairment of DNA synthesis, resulting in depletion of lymphocytes.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- MAVENCLAD · CLADRIBINE 10MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Cladribine" as an intervention, any sponsor and status, largest first.
Goethe UniversityAcademic, hospital or other
NCT00198991 · 1,883 participants · Start Apr 2003 · Primary completion Jun 30, 2011
Drug: Cyclophosphamide; Dexamethasone and 16 more · For: Adult Acute Lymphocytic Leukemia
Sites: Frankfurt, Germany
- Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy CombinationsPivotal-lookingStatus unknown
Cardiff UniversityAcademic, hospital or other
NCT02272478 · 1,600 participants (planned) · Start Oct 30, 2014 · Primary completion Feb 2021
Drug: Arm A Mylotarg plus DA Versus CPX-351; Arm B Vosaroxin and Decitabine and 4 more · For: Acute Myeloid Leukaemia; Myelodysplastic Syndrome
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 87 sites in all
- LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisPivotal-lookingActive, not recruiting
North American Consortium for HistiocytosisAcademic, hospital or other
NCT02205762 · 1,400 participants · Start Nov 2, 2016 · Primary completion Nov 2031
Drug: Prednisone; Vinblastine and 6 more · For: Langerhans Cell Histiocytosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 42 sites in all
- A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)Pivotal-lookingCompleted
EMD SeronoIndustry
NCT00213135 · 1,326 participants · Start Apr 2005 · Primary completion Nov 2008
Drug: Cladribine 5.25 mg/kg; Cladribine 3.5 mg/kg · For: Multiple Sclerosis, Relapsing-Remitting
- CLARITY Extension StudyPivotal-lookingCompleted
EMD Serono Research & Development Institute, Inc.Industry
NCT00641537 · 867 participants · Start Feb 29, 2008 · Primary completion Dec 31, 2011
Drug: Cladribine; Placebo and 3 more · For: Relapsing-Remitting Multiple Sclerosis
Sites: Boulder, Colorado; Atlanta, Georgia; Chicago, Illinois · 116 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)Pivotal-lookingCompleted
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT02323022 · 618 participants · Start Dec 2014 · Primary completion Mar 2020
Drug: IAC regimen; IA regimen · For: Acute Myeloid Leukemia
Sites: Suzhou, China
- Oral Cladribine in Early Multiple Sclerosis (MS)Pivotal-lookingCompleted
EMD Serono Research & Development Institute, Inc.Industry
NCT00725985 · 617 participants · Start Dec 31, 2008 · Primary completion Jul 31, 2011
Drug: Cladribine; Placebo and 1 more · For: Multiple Sclerosis
Sites: Phoenix, Arizona; Newport Beach, California; Denver, Colorado · 158 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue848
- headache713
- lymphocyte count decreased507
- multiple sclerosis relapse494
- nausea437
- pneumonia418
- white blood cell count decreased376
- off label use339
- drug ineffective309
- pyrexia294
- urinary tract infection288
- multiple sclerosis270
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 24 |
| 2005 | 26 |
| 2006 | 18 |
| 2007 | 17 |
| 2008 | 19 |
| 2009 | 29 |
| 2010 | 53 |
| 2011 | 120 |
| 2012 | 125 |
| 2013 | 90 |
| 2014 | 56 |
| 2015 | 73 |
| 2016 | 71 |
| 2017 | 117 |
| 2018 | 109 |
| 2019 | 705 |
| 2020 | 954 |
| 2021 | 1,056 |
| 2022 | 1,134 |
| 2023 | 1,333 |
| 2024 | 1,333 |
| 2025 | 1,427 |
| 2026 | 1,078 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mavenclad (Cladribine)
2024 spending
$178M
Beneficiaries
1,315
2,409 claims
Per beneficiary
$135,506
$10,105.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $110,753,144 |
| 2021 | $144,597,434 |
| 2022 | $126,761,629 |
| 2023 | $156,344,544 |
| 2024 | $178,190,392 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Kadia TM, Reville PK, Wang X, et al. · J Clin Oncol 2022 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G, Comi G, Cook S, et al. · N Engl J Med 2010 · Multicenter Study, Randomized Controlled Trial
- Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D, Arons E, Stetler-Stevenson M, et al. · J Clin Oncol 2020 · Clinical Trial, Phase II, Randomized Controlled Trial
- Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.
Marvin-Peek J, Jen WY, Kantarjian HM, et al. · Leuk Lymphoma 2024 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.
Tramacere I, Virgili G, Perduca V, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Emd Serono INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.